Method for depletion or removal of endotoxin from an endotoxin-containing source or potentially endotoxin-containing source
A method for depletion or removal of endotoxins from a known or suspected endotoxin-containing source by virtue of a solid phase extraction material in an essentially aqueous system comprising the steps of—providing a known or suspected endotoxin-containing source, —contacting the known or suspected endotoxin-containing source with a positively charged solid phase material having a surface on which ferric iron is immobilised, wherein the solid phase extraction material has immobilised the ferric iron by (2-aminoethyl)amine (TREN) ligand—incubating the known or suspected endotoxin-containing source for a period of time sufficient to bind endotoxin to the porous solid phase material, —separating the solid phase material from the essentially aqueous system, —optionally isolating the essentially aqueous system freed or depleted from endotoxin.
1 . A method for improved depletion or removal of endotoxins from a known or suspected endotoxin-containing source by virtue of a solid phase extraction material in an essentially aqueous system comprising the steps of
providing a known or suspected endotoxin-containing source solution;
contacting the known or suspected endotoxin-containing source solution with a positively charged solid phase material having a surface on which ferric iron is immobilized, wherein the solid phase material has immobilized the ferric iron by tris(2-aminoethyl)amine (TREN) ligand;
incubating the known or suspected endotoxin-containing source solution for a period of time sufficient to bind endotoxin to the solid phase material and to form an incubated solution; and
separating the solid phase material from the incubating solution to obtain a product solution with reduced endotoxin levels relative to the source solution, wherein the endotoxin levels are lower than endotoxin levels obtained by a process that is equivalent except for using iminodiacetic acid (IDA) chelating ligands.
2 . The method of claim 1 , wherein the solid-phase extraction is a method selected from the group consisting of chromatography, filtration, co-precipitation and combinations thereof.
3 . The method of claim 1 , wherein the solid phase material comprises a chromatographic material which depletes or removes the endotoxin by ferric iron chelation from the known or suspected endotoxin-containing source solution.
4 . The method of claim 1 , wherein the known or suspected endotoxin-containing source solution is selected for the manufacturing of low-endotoxin bacteriophages containing compositions, for the purification of recombinantly produced proteins, for removal of endotoxins and/or viruses from cell culture ingredients to be used in preparation of recombinantly produced proteins, and for removal of endotoxins from in vitro diagnostic assay reagents.
5 . The method of claim 1 , wherein the method is performed in combination with other purification methods.
6 . The method of claim 5 , wherein the other purification methods are selected from hydrophobic interaction chromatography, preferential exclusion chromatography and anion exchange chromatography.
7 . The method according to claim 1 , further comprising isolating the essentially aqueous system freed from or depleted of endotoxin after the separating step.
8 . The method of claim 4 , wherein the purification of recombinantly produced proteins is for therapeutic applications.
9 . The method of claim 1 , wherein the incubating is performed at a pH of 7.7±1.0.
10 . The method of claim 1 , wherein the incubating is performed with a salt concentration up to 100 mM distinct from the buffer.
11 . The method of claim 1 , wherein the incubating is performed with buffers comprising 1% to 50% glycerol.
12 . The method of claim 1 , wherein the incubating is performed at a pH of 7.7±1.0, with a salt concentration from 20 mM to 100 mM, with buffers comprising 1% to 50% glycerol.
13 . The method of claim 1 , wherein the endotoxin levels are at least 14 times lower than endotoxin levels obtained by a process that is equivalent except for using IDA chelating-ligands.
14 . The method of claim 1 , wherein the solid phase material has a charge of at least +3 per ligand.
15 . The method of claim 1 , wherein the product solution has an endotoxin concentration of less than 1 EU per 10 9 infective bacteriophage particles.